HPS Pharmacies wish to advise that Baxter Healthcare, in consultation with the Therapeutic Goods Administration (TGA), have given notice of a drug quarantine for Baxter Potassium Chloride 10mmol and 0.29% Sodium Chloride 100mL intravenous infusion bags as follows:
Baxter Potassium Chloride and Sodium Chloride Intravenous Infusion
Potassium chloride 10mmol and Sodium Chloride 0.29%
The only batch affected by this recall is BN: W66L5 with an expiry date of January 2020.
This drug quarantine request has been initiated as a precautionary measure pending further investigation into possible microbial contamination. One report of an adverse event occurring during the infusion of this product has been received. The bag in question was sent for microbiological testing where it returned a positive result. It is considered likely that this single positive result is due to the bag already having been opened. However, further testing is required.
Please inspect your stock and quarantine all affected products until further notice. If HPS Pharmacies provide imprest management services to your facility, an HPS representative will inspect all stock stored in the designated imprest areas at the earliest opportunity. An HPS Pharmacies staff member will contact senior medical and nursing staff if there is an immediate impact to your facility.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies, or Baxter on 1800 229 837.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates